This range of actions has positioned GLP-1 RAs above other medications to treat type 2 diabetes (T2D), and as the first-line treatment when either therapy enhancement with an injectable agent is required or the patient is at high cardiovascular risk (CVR) (7, 8). Here, GLP1R is linked to type 2 diabetes mellitus.